As GLP-1 receptor agonists become an increasingly important component of obesity management, attention is shifting from clinical efficacy to the systems that determine whether patients can access these therapies. While evidence supporting GLP-1 medicines has led multiple medical societies to update treatment guidelines, significant administrative and technological barriers continue to affect prescribing and reimbursement processes.
According to Dr. Quoc N. Dang, the primary challenge is no longer whether these therapies work, but whether healthcare infrastructure can effectively support access to them. Current prior authorization (PA) processes often require extensive documentation, including body mass index thresholds, comorbidity records, previous treatment history, and evidence of dietary counseling. These requirements vary by payer and frequently necessitate additional administrative work from clinicians and their staff.
The burden of prior authorization has been well documented. The American Medical Association’s 2023 Prior Authorization Physician Survey found that 93% of physicians reported delays in patient care due to prior authorization requirements, while 82% said the process sometimes resulted in patients abandoning recommended treatment. For GLP-1 therapies specifically, commercial payer denial rates have been reported between 30% and 50%, with successful appeals often requiring weeks of follow-up documentation.
A central concern is the technology supporting these workflows. Despite the availability of electronic prior authorization standards such as NCPDP SCRIPT and broader regulatory efforts to encourage digital adoption, many requests for specialty medications continue to rely on fax-based processes. Even when electronic portals are available, they often operate separately from electronic health record (EHR) systems, requiring clinical staff to manually enter information already contained within patient records.
Dr. Dang argues that these inefficiencies create meaningful barriers to care. “For a drug class where early treatment initiation correlates with better long term adherence, a two to four week authorization delay is not a paperwork inconvenience — it is a clinical access barrier.”
Beyond authorization challenges, the article highlights limitations in outcomes tracking. Data needed to evaluate treatment effectiveness and support value-based reimbursement arrangements often remains fragmented across EHRs, pharmacy systems, and payer claims databases. As a result, stakeholders struggle to generate comprehensive real-world evidence regarding long-term outcomes and healthcare utilization.
Potential solutions already exist through standards such as HL7 FHIR, the Da Vinci Prior Authorization Support implementation guide, and NCPDP SCRIPT. Dr. Dang contends that broader implementation of EHR-integrated prior authorization, real-time formulary visibility, and standardized outcomes reporting could significantly improve patient access and support more effective use of GLP-1 therapies across healthcare systems.
Click here for the original news story.
